<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000957</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>20</s160></s100><s200><s210>1</s210><s211>488</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 1Met Gly Arg Pro Leu His Leu Val Leu Leu Ser Ala Ser Leu Ala Gly1               5                   10                  15Leu Leu Leu Leu Gly Glu Ser Leu Phe Ile Arg Arg Glu Gln Ala Asn            20                  25                  30Asn Ile Leu Ala Arg Val Thr Arg Ala Asn Ser Phe Leu Glu Glu Met        35                  40                  45Lys Lys Gly His Leu Glu Arg Glu Cys Met Glu Glu Thr Cys Ser Tyr    50                  55                  60Glu Glu Ala Arg Glu Val Phe Glu Asp Ser Asp Lys Thr Asn Glu Phe65                  70                  75                  80Trp Asn Lys Tyr Lys Asp Gly Asp Gln Cys Glu Thr Ser Pro Cys Gln                85                  90                  95Asn Gln Gly Lys Cys Lys Asp Gly Leu Gly Glu Tyr Thr Cys Thr Cys            100                 105                 110Leu Glu Gly Phe Glu Gly Lys Asn Cys Glu Leu Phe Thr Arg Lys Leu        115                 120                 125Cys Ser Leu Asp Asn Gly Asp Cys Asp Gln Phe Cys His Glu Glu Gln    130                 135                 140Asn Ser Val Val Cys Ser Cys Ala Arg Gly Tyr Thr Leu Ala Asp Asn145                 150                 155                 160Gly Lys Ala Cys Ile Pro Thr Gly Pro Tyr Pro Cys Gly Lys Gln Thr                165                 170                 175Leu Glu Arg Arg Lys Arg Ser Val Ala Gln Ala Thr Ser Ser Ser Gly            180                 185                 190Glu Ala Pro Asp Ser Ile Thr Trp Lys Pro Tyr Asp Ala Ala Asp Leu        195                 200                 205Asp Pro Thr Glu Asn Pro Phe Asp Leu Leu Asp Phe Asn Gln Thr Gln    210                 215                 220Pro Glu Arg Gly Asp Asn Asn Leu Thr Arg Ile Val Gly Gly Gln Glu225                 230                 235                 240Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu Leu Ile Asn Glu Glu                245                 250                 255Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser Glu Phe Tyr Ile Leu            260                 265                 270Thr Ala Ala His Cys Leu Tyr Gln Ala Lys Arg Phe Lys Val Arg Val        275                 280                 285Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly Glu Ala Val His Glu    290                 295                 300Val Glu Val Val Ile Lys His Asn Arg Phe Thr Lys Glu Thr Tyr Asp305                 310                 315                 320Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile Thr Phe Arg Met                325                 330                 335Asn Val Ala Pro Ala Cys Leu Pro Glu Arg Asp Trp Ala Glu Ser Thr            340                 345                 350Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe Gly Arg Thr His        355                 360                 365Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys Met Leu Glu Val Pro Tyr    370                 375                 380Val Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser Phe Ile Ile Thr Gln385                 390                 395                 400Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln Glu Asp Ala Cys Gln                405                 410                 415Gly Asp Ser Gly Gly Pro His Val Thr Arg Phe Lys Asp Thr Tyr Phe            420                 425                 430Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala Arg Lys Gly Lys        435                 440                 445Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu Lys Trp Ile Asp Arg    450                 455                 460Ser Met Lys Thr Arg Gly Leu Pro Lys Ala Lys Ser His Ala Pro Glu465                 470                 475                 480Val Ile Thr Ser Ser Pro Leu Lys                485</s400><s200><s210>2</s210><s211>1560</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 2gactttgctc cagcagcctg tcccagtgag gacagggaca cagtactcgg ccacaccatg     60gggcgcccac tgcacctcgt cctgctcagt gcctccctgg ctggcctcct gctgctcggg    120gaaagtctgt tcatccgcag ggagcaggcc aacaacatcc tggcgagggt cacgagggcc    180aattcctttc ttgaagagat gaagaaagga cacctcgaaa gagagtgcat ggaagagacc    240tgctcatacg aagaggcccg cgaggtcttt gaggacagcg acaagacgaa tgaattctgg    300aataaataca aagatggcga ccagtgtgag accagtcctt gccagaacca gggcaaatgt    360aaagacggcc tcggggaata cacctgcacc tgtttagaag gattcgaagg caaaaactgt    420gaattattca cacggaagct ctgcagcctg gacaacgggg actgtgacca gttctgccac    480gaggaacaga actctgtggt gtgctcctgc gcccgcgggt acaccctggc tgacaacggc    540aaggcctgca ttcccacagg gccctacccc tgtgggaaac agaccctgga acgcaggaag    600aggtcagtgg cccaggccac cagcagcagc ggggaggccc ctgacagcat cacatggaag    660ccatatgatg cagccgacct ggaccccacc gagaacccct tcgacctgct tgacttcaac    720cagacgcagc ctgagagggg cgacaacaac ctcaccagga tcgtgggagg ccaggaatgc    780aaggacgggg agtgtccctg gcaggccctg ctcatcaatg aggaaaacga gggtttctgt    840ggtggaacca ttctgagcga gttctacatc ctaacggcag cccactgtct ctaccaagcc    900aagagattca aggtgagggt aggggaccgg aacacggagc aggaggaggg cggtgaggcg    960gtgcacgagg tggaggtggt catcaagcac aaccggttca caaaggagac ctatgacttc   1020gacatcgccg tgctccggct caagaccccc atcaccttcc gcatgaacgt ggcgcctgcc   1080tgcctccccg agcgtgactg ggccgagtcc acgctgatga cgcagaagac ggggattgtg   1140agcggcttcg ggcgcaccca cgagaagggc cggcagtcca ccaggctcaa gatgctggag   1200gtgccctacg tggaccgcaa cagctgcaag ctgtccagca gcttcatcat cacccagaac   1260atgttctgtg ccggctacga caccaagcag gaggatgcct gccaggggga cagcgggggc   1320ccgcacgtca cccgcttcaa ggacacctac ttcgtgacag gcatcgtcag ctggggagag   1380ggctgtgccc gtaaggggaa gtacgggatc tacaccaagg tcaccgcctt cctcaagtgg   1440atcgacaggt ccatgaaaac caggggcttg cccaaggcca agagccatgc cccggaggtc   1500ataacgtcct ctccattaaa gtgagatccc actcaaaaaa aaaaaaaaaa aaaaaaaaaa   1560</s400><s200><s210>3</s210><s211>448</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 3Ala Asn Ser Phe Leu Glu Glu Met Lys Lys Gly His Leu Glu Arg Glu1               5                   10                  15Cys Met Glu Glu Thr Cys Ser Tyr Glu Glu Ala Arg Glu Val Phe Glu            20                  25                  30Asp Ser Asp Lys Thr Asn Glu Phe Trp Asn Lys Tyr Lys Asp Gly Asp        35                  40                  45Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys Lys Asp Gly    50                  55                  60Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu Gly Lys Asn65                  70                  75                  80Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn Gly Asp Cys                85                  90                  95Asp Gln Phe Cys His Glu Glu Gln Asn Ser Val Val Cys Ser Cys Ala            100                 105                 110Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile Pro Thr Gly        115                 120                 125Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu Arg Arg Lys Arg Ser Val    130                 135                 140Ala Gln Ala Thr Ser Ser Ser Gly Glu Ala Pro Asp Ser Ile Thr Trp145                 150                 155                 160Lys Pro Tyr Asp Ala Ala Asp Leu Asp Pro Thr Glu Asn Pro Phe Asp                165                 170                 175Leu Leu Asp Phe Asn Gln Thr Gln Pro Glu Arg Gly Asp Asn Asn Leu            180                 185                 190Thr Arg Ile Val Gly Gly Gln Glu Cys Lys Asp Gly Glu Cys Pro Trp        195                 200                 205Gln Ala Leu Leu Ile Asn Glu Glu Asn Glu Gly Phe Cys Gly Gly Thr    210                 215                 220Ile Leu Ser Glu Phe Tyr Ile Leu Thr Ala Ala His Cys Leu Tyr Gln225                 230                 235                 240Ala Lys Arg Phe Lys Val Arg Val Gly Asp Arg Asn Thr Glu Gln Glu                245                 250                 255Glu Gly Gly Glu Ala Val His Glu Val Glu Val Val Ile Lys His Asn            260                 265                 270Arg Phe Thr Lys Glu Thr Tyr Asp Phe Asp Ile Ala Val Leu Arg Leu        275                 280                 285Lys Thr Pro Ile Thr Phe Arg Met Asn Val Ala Pro Ala Cys Leu Pro    290                 295                 300Glu Arg Asp Trp Ala Glu Ser Thr Leu Met Thr Gln Lys Thr Gly Ile305                 310                 315                 320Val Ser Gly Phe Gly Arg Thr His Glu Lys Gly Arg Gln Ser Thr Arg                325                 330                 335Leu Lys Met Leu Glu Val Pro Tyr Val Asp Arg Asn Ser Cys Lys Leu            340                 345                 350Ser Ser Ser Phe Ile Ile Thr Gln Asn Met Phe Cys Ala Gly Tyr Asp        355                 360                 365Thr Lys Gln Glu Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro His Val    370                 375                 380Thr Arg Phe Lys Asp Thr Tyr Phe Val Thr Gly Ile Val Ser Trp Gly385                 390                 395                 400Glu Gly Cys Ala Arg Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Thr                405                 410                 415Ala Phe Leu Lys Trp Ile Asp Arg Ser Met Lys Thr Arg Gly Leu Pro            420                 425                 430Lys Ala Lys Ser His Ala Pro Glu Val Ile Thr Ser Ser Pro Leu Lys        435                 440                 445</s400><s200><s210>4</s210><s211>349</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 4Lys Asp Gly Asp Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys1               5                   10                  15Cys Lys Asp Gly Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe            20                  25                  30Glu Gly Lys Asn Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp        35                  40                  45Asn Gly Asp Cys Asp Gln Phe Cys His Glu Glu Gln Asn Ser Val Val    50                  55                  60Cys Ser Cys Ala Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys65                  70                  75                  80Ile Pro Thr Gly Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu Arg Ile                85                  90                  95Val Gly Gly Gln Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu            100                 105                 110Leu Ile Asn Glu Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser        115                 120                 125Glu Phe Tyr Ile Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys Arg    130                 135                 140Phe Lys Val Arg Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly145                 150                 155                 160Glu Ala Val His Glu Val Glu Val Val Ile Lys His Asn Arg Phe Thr                165                 170                 175Lys Glu Thr Tyr Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro            180                 185                 190Ile Thr Phe Arg Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg Asp        195                 200                 205Trp Ala Glu Ser Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly    210                 215                 220Phe Gly Arg Thr His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys Met225                 230                 235                 240Leu Glu Val Pro Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser                245                 250                 255Phe Ile Ile Thr Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln            260                 265                 270Glu Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro His Val Thr Arg Phe        275                 280                 285Lys Asp Thr Tyr Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys    290                 295                 300Ala Arg Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu305                 310                 315                 320Lys Trp Ile Asp Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala Lys                325                 330                 335Ser His Ala Pro Glu Val Ile Thr Ser Ser Pro Leu Lys            340                 345</s400><s200><s210>5</s210><s211>348</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 5Asp Gly Asp Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys1               5                   10                  15Lys Asp Gly Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu            20                  25                  30Gly Lys Asn Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn        35                  40                  45Gly Asp Cys Asp Gln Phe Cys His Glu Glu Gln Asn Ser Val Val Cys    50                  55                  60Ser Cys Ala Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile65                  70                  75                  80Pro Thr Gly Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu Arg Ile Val                85                  90                  95Gly Gly Gln Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu Leu            100                 105                 110Ile Asn Glu Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser Glu        115                 120                 125Phe Tyr Ile Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys Arg Phe    130                 135                 140Lys Val Arg Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly Glu145                 150                 155                 160Ala Val His Glu Val Glu Val Val Ile Lys His Asn Arg Phe Thr Lys                165                 170                 175Glu Thr Tyr Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile            180                 185                 190Thr Phe Arg Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg Asp Trp        195                 200                 205Ala Glu Ser Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe    210                 215                 220Gly Arg Thr His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys Met Leu225                 230                 235                 240Glu Val Pro Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser Phe                245                 250                 255Ile Ile Thr Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln Glu            260                 265                 270Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro His Val Thr Arg Phe Lys        275                 280                 285Asp Thr Tyr Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala    290                 295                 300Arg Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu Lys305                 310                 315                 320Trp Ile Asp Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala Lys Ser                325                 330                 335His Ala Pro Glu Val Ile Thr Ser Ser Pro Leu Lys            340                 345</s400><s200><s210>6</s210><s211>393</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 6Ala Asn Ser Phe Leu Glu Glu Met Lys Lys Gly His Leu Glu Arg Glu1               5                   10                  15Cys Met Glu Glu Thr Cys Ser Tyr Glu Glu Ala Arg Glu Val Phe Glu            20                  25                  30Asp Ser Asp Lys Thr Asn Glu Phe Trp Asn Lys Tyr Lys Asp Gly Asp        35                  40                  45Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys Lys Asp Gly    50                  55                  60Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu Gly Lys Asn65                  70                  75                  80Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn Gly Asp Cys                85                  90                  95Asp Gln Phe Cys His Glu Glu Gln Asn Ser Val Val Cys Ser Cys Ala            100                 105                 110Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile Pro Thr Gly        115                 120                 125Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu Arg Ile Val Gly Gly Gln    130                 135                 140Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu Leu Ile Asn Glu145                 150                 155                 160Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser Glu Phe Tyr Ile                165                 170                 175Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys Arg Phe Lys Val Arg            180                 185                 190Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly Glu Ala Val His        195                 200                 205Glu Val Glu Val Val Ile Lys His Asn Arg Phe Thr Lys Glu Thr Tyr    210                 215                 220Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile Thr Phe Arg225                 230                 235                 240Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg Asp Trp Ala Glu Ser                245                 250                 255Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe Gly Arg Thr            260                 265                 270His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys Met Leu Glu Val Pro        275                 280                 285Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser Phe Ile Ile Thr    290                 295                 300Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln Glu Asp Ala Cys305                 310                 315                 320Gln Gly Asp Ser Gly Gly Pro His Val Thr Arg Phe Lys Asp Thr Tyr                325                 330                 335Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala Arg Lys Gly            340                 345                 350Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu Lys Trp Ile Asp        355                 360                 365Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala Lys Ser His Ala Pro    370                 375                 380Glu Val Ile Thr Ser Ser Pro Leu Lys385                 390</s400><s200><s210>7</s210><s211>393</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220><s220><s221>MOD_RES</s221><s222>(6)..(7)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(14)..(14)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(16)..(16)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(19)..(20)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(25)..(26)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(29)..(29)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(32)..(32)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(39)..(39)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220></s200><s400> 7Ala Asn Ser Phe Leu Xaa Xaa Met Lys Lys Gly His Leu Xaa Arg Xaa1               5                   10                  15Cys Met Xaa Xaa Thr Cys Ser Tyr Xaa Xaa Ala Arg Xaa Val Phe Xaa            20                  25                  30Asp Ser Asp Lys Thr Asn Xaa Phe Trp Asn Lys Tyr Lys Asp Gly Asp        35                  40                  45Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys Lys Asp Gly    50                  55                  60Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu Gly Lys Asn65                  70                  75                  80Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn Gly Asp Cys                85                  90                  95Asp Gln Phe Cys His Glu Glu Gln Asn Ser Val Val Cys Ser Cys Ala            100                 105                 110Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile Pro Thr Gly        115                 120                 125Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu Arg Ile Val Gly Gly Gln    130                 135                 140Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu Leu Ile Asn Glu145                 150                 155                 160Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser Glu Phe Tyr Ile                165                 170                 175Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys Arg Phe Lys Val Arg            180                 185                 190Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly Glu Ala Val His        195                 200                 205Glu Val Glu Val Val Ile Lys His Asn Arg Phe Thr Lys Glu Thr Tyr    210                 215                 220Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile Thr Phe Arg225                 230                 235                 240Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg Asp Trp Ala Glu Ser                245                 250                 255Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe Gly Arg Thr            260                 265                 270His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys Met Leu Glu Val Pro        275                 280                 285Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser Phe Ile Ile Thr    290                 295                 300Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln Glu Asp Ala Cys305                 310                 315                 320Gln Gly Asp Ser Gly Gly Pro His Val Thr Arg Phe Lys Asp Thr Tyr                325                 330                 335Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala Arg Lys Gly            340                 345                 350Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu Lys Trp Ile Asp        355                 360                 365Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala Lys Ser His Ala Pro    370                 375                 380Glu Val Ile Thr Ser Ser Pro Leu Lys385                 390</s400><s200><s210>8</s210><s211>139</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220><s220><s221>MOD_RES</s221><s222>(6)..(7)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(14)..(14)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(16)..(16)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(19)..(20)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(25)..(26)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(29)..(29)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(32)..(32)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220><s220><s221>MOD_RES</s221><s222>(39)..(39)</s222><s223>Gamma-Carboxyglutamic acid</s223></s220></s200><s400> 8Ala Asn Ser Phe Leu Xaa Xaa Met Lys Lys Gly His Leu Xaa Arg Xaa1               5                   10                  15Cys Met Xaa Xaa Thr Cys Ser Tyr Xaa Xaa Ala Arg Xaa Val Phe Xaa            20                  25                  30Asp Ser Asp Lys Thr Asn Xaa Phe Trp Asn Lys Tyr Lys Asp Gly Asp        35                  40                  45Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys Lys Asp Gly    50                  55                  60Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu Gly Lys Asn65                  70                  75                  80Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn Gly Asp Cys                85                  90                  95Asp Gln Phe Cys His Glu Glu Gln Asn Ser Val Val Cys Ser Cys Ala            100                 105                 110Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile Pro Thr Gly        115                 120                 125Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu Arg    130                 135</s400><s200><s210>9</s210><s211>254</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 9Ile Val Gly Gly Gln Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala1               5                   10                  15Leu Leu Ile Asn Glu Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu            20                  25                  30Ser Glu Phe Tyr Ile Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys        35                  40                  45Arg Phe Lys Val Arg Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly    50                  55                  60Gly Glu Ala Val His Glu Val Glu Val Val Ile Lys His Asn Arg Phe65                  70                  75                  80Thr Lys Glu Thr Tyr Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr                85                  90                  95Pro Ile Thr Phe Arg Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg            100                 105                 110Asp Trp Ala Glu Ser Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser        115                 120                 125Gly Phe Gly Arg Thr His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys    130                 135                 140Met Leu Glu Val Pro Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser145                 150                 155                 160Ser Phe Ile Ile Thr Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys                165                 170                 175Gln Glu Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro His Val Thr Arg            180                 185                 190Phe Lys Asp Thr Tyr Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly        195                 200                 205Cys Ala Arg Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe    210                 215                 220Leu Lys Trp Ile Asp Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala225                 230                 235                 240Lys Ser His Ala Pro Glu Val Ile Thr Ser Ser Pro Leu Lys                245                 250</s400><s200><s210>10</s210><s211>349</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220><s220><s221>MOD_RES</s221><s222>(280)..(280)</s222><s223>Dehydroalanine</s223></s220></s200><s400> 10Lys Asp Gly Asp Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys1               5                   10                  15Cys Lys Asp Gly Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe            20                  25                  30Glu Gly Lys Asn Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp        35                  40                  45Asn Gly Asp Cys Asp Gln Phe Cys His Glu Glu Gln Asn Ser Val Val    50                  55                  60Cys Ser Cys Ala Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys65                  70                  75                  80Ile Pro Thr Gly Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu Arg Ile                85                  90                  95Val Gly Gly Gln Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu            100                 105                 110Leu Ile Asn Glu Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser        115                 120                 125Glu Phe Tyr Ile Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys Arg    130                 135                 140Phe Lys Val Arg Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly145                 150                 155                 160Glu Ala Val His Glu Val Glu Val Val Ile Lys His Asn Arg Phe Thr                165                 170                 175Lys Glu Thr Tyr Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro            180                 185                 190Ile Thr Phe Arg Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg Asp        195                 200                 205Trp Ala Glu Ser Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly    210                 215                 220Phe Gly Arg Thr His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys Met225                 230                 235                 240Leu Glu Val Pro Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser                245                 250                 255Phe Ile Ile Thr Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln            260                 265                 270Glu Asp Ala Cys Gln Gly Asp Ala Gly Gly Pro His Val Thr Arg Phe        275                 280                 285Lys Asp Thr Tyr Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys    290                 295                 300Ala Arg Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu305                 310                 315                 320Lys Trp Ile Asp Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala Lys                325                 330                 335Ser His Ala Pro Glu Val Ile Thr Ser Ser Pro Leu Lys            340                 345</s400><s200><s210>11</s210><s211>348</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 11Asp Gly Asp Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys1               5                   10                  15Lys Asp Gly Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu            20                  25                  30Gly Lys Asn Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn        35                  40                  45Gly Asp Cys Asp Gln Phe Cys His Glu Glu Gln Asn Ser Val Val Cys    50                  55                  60Ser Cys Ala Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile65                  70                  75                  80Pro Thr Gly Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu Arg Ile Val                85                  90                  95Gly Gly Gln Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu Leu            100                 105                 110Ile Asn Glu Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser Glu        115                 120                 125Phe Tyr Ile Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys Arg Phe    130                 135                 140Lys Val Arg Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly Glu145                 150                 155                 160Ala Val His Glu Val Glu Val Val Ile Lys His Asn Arg Phe Thr Lys                165                 170                 175Glu Thr Tyr Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile            180                 185                 190Thr Phe Arg Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg Asp Trp        195                 200                 205Ala Glu Ser Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe    210                 215                 220Gly Arg Thr His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys Met Leu225                 230                 235                 240Glu Val Pro Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser Phe                245                 250                 255Ile Ile Thr Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln Glu            260                 265                 270Asp Ala Cys Gln Gly Asp Ala Gly Gly Pro His Val Thr Arg Phe Lys        275                 280                 285Asp Thr Tyr Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala    290                 295                 300Arg Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu Lys305                 310                 315                 320Trp Ile Asp Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala Lys Ser                325                 330                 335His Ala Pro Glu Val Ile Thr Ser Ser Pro Leu Lys            340                 345</s400><s200><s210>12</s210><s211>365</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 12Ala Asn Ser Phe Leu Phe Trp Asn Lys Tyr Lys Asp Gly Asp Gln Cys1               5                   10                  15Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys Lys Asp Gly Leu Gly            20                  25                  30Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu Gly Lys Asn Cys Glu        35                  40                  45Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn Gly Asp Cys Asp Gln    50                  55                  60Phe Cys His Glu Glu Gln Asn Ser Val Val Cys Ser Cys Ala Arg Gly65                  70                  75                  80Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile Pro Thr Gly Pro Tyr                85                  90                  95Pro Cys Gly Lys Gln Thr Leu Glu Arg Arg Lys Arg Arg Lys Arg Ile            100                 105                 110Val Gly Gly Gln Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu        115                 120                 125Leu Ile Asn Glu Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser    130                 135                 140Glu Phe Tyr Ile Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys Arg145                 150                 155                 160Phe Lys Val Arg Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly                165                 170                 175Glu Ala Val His Glu Val Glu Val Val Ile Lys His Asn Arg Phe Thr            180                 185                 190Lys Glu Thr Tyr Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro        195                 200                 205Ile Thr Phe Arg Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg Asp    210                 215                 220Trp Ala Glu Ser Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly225                 230                 235                 240Phe Gly Arg Thr His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys Met                245                 250                 255Leu Glu Val Pro Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser            260                 265                 270Phe Ile Ile Thr Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln        275                 280                 285Glu Asp Ala Cys Gln Gly Asp Ala Gly Gly Pro His Val Thr Arg Phe    290                 295                 300Lys Asp Thr Tyr Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys305                 310                 315                 320Ala Arg Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu                325                 330                 335Lys Trp Ile Asp Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala Lys            340                 345                 350Ser His Ala Pro Glu Val Ile Thr Ser Ser Pro Leu Lys        355                 360                 365</s400><s200><s210>13</s210><s211>359</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 13Ala Asn Ser Phe Leu Phe Trp Asn Lys Tyr Lys Asp Gly Asp Gln Cys1               5                   10                  15Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys Lys Asp Gly Leu Gly            20                  25                  30Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu Gly Lys Asn Cys Glu        35                  40                  45Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn Gly Asp Cys Asp Gln    50                  55                  60Phe Cys His Glu Glu Gln Asn Ser Val Val Cys Ser Cys Ala Arg Gly65                  70                  75                  80Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile Pro Thr Gly Pro Tyr                85                  90                  95Pro Cys Gly Lys Gln Thr Leu Glu Arg Ile Val Gly Gly Gln Glu Cys            100                 105                 110Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu Leu Ile Asn Glu Glu Asn        115                 120                 125Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser Glu Phe Tyr Ile Leu Thr    130                 135                 140Ala Ala His Cys Leu Tyr Gln Ala Lys Arg Phe Lys Val Arg Val Gly145                 150                 155                 160Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly Glu Ala Val His Glu Val                165                 170                 175Glu Val Val Ile Lys His Asn Arg Phe Thr Lys Glu Thr Tyr Asp Phe            180                 185                 190Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile Thr Phe Arg Met Asn        195                 200                 205Val Ala Pro Ala Cys Leu Pro Glu Arg Asp Trp Ala Glu Ser Thr Leu    210                 215                 220Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe Gly Arg Thr His Glu225                 230                 235                 240Lys Gly Arg Gln Ser Thr Arg Leu Lys Met Leu Glu Val Pro Tyr Val                245                 250                 255Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser Phe Ile Ile Thr Gln Asn            260                 265                 270Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln Glu Asp Ala Cys Gln Gly        275                 280                 285Asp Ala Gly Gly Pro His Val Thr Arg Phe Lys Asp Thr Tyr Phe Val    290                 295                 300Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala Arg Lys Gly Lys Tyr305                 310                 315                 320Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu Lys Trp Ile Asp Arg Ser                325                 330                 335Met Lys Thr Arg Gly Leu Pro Lys Ala Lys Ser His Ala Pro Glu Val            340                 345                 350Ile Thr Ser Ser Pro Leu Lys        355</s400><s200><s210>14</s210><s211>105</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 14Ala Asn Ser Phe Leu Phe Trp Asn Lys Tyr Lys Asp Gly Asp Gln Cys1               5                   10                  15Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys Lys Asp Gly Leu Gly            20                  25                  30Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu Gly Lys Asn Cys Glu        35                  40                  45Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn Gly Asp Cys Asp Gln    50                  55                  60Phe Cys His Glu Glu Gln Asn Ser Val Val Cys Ser Cys Ala Arg Gly65                  70                  75                  80Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile Pro Thr Gly Pro Tyr                85                  90                  95Pro Cys Gly Lys Gln Thr Leu Glu Arg            100                 105</s400><s200><s210>15</s210><s211>254</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 15Ile Val Gly Gly Gln Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala1               5                   10                  15Leu Leu Ile Asn Glu Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu            20                  25                  30Ser Glu Phe Tyr Ile Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys        35                  40                  45Arg Phe Lys Val Arg Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly    50                  55                  60Gly Glu Ala Val His Glu Val Glu Val Val Ile Lys His Asn Arg Phe65                  70                  75                  80Thr Lys Glu Thr Tyr Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr                85                  90                  95Pro Ile Thr Phe Arg Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg            100                 105                 110Asp Trp Ala Glu Ser Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser        115                 120                 125Gly Phe Gly Arg Thr His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys    130                 135                 140Met Leu Glu Val Pro Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser145                 150                 155                 160Ser Phe Ile Ile Thr Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys                165                 170                 175Gln Glu Asp Ala Cys Gln Gly Asp Ala Gly Gly Pro His Val Thr Arg            180                 185                 190Phe Lys Asp Thr Tyr Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly        195                 200                 205Cys Ala Arg Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe    210                 215                 220Leu Lys Trp Ile Asp Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala225                 230                 235                 240Lys Ser His Ala Pro Glu Val Ile Thr Ser Ser Pro Leu Lys                245                 250</s400><s200><s210>16</s210><s211>1218</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 16atggggcgcc cactgcacct cgtcctgctc agtgcctccc tggctggcct cctgctgctc     60ggggaaagtc tgttcatccg cagggagcag gccaacaaca tcctggcgag ggtcacgagg    120gccaattcct ttcttttctg gaataaatac aaagatggcg accagtgtga gaccagtcct    180tgccagaacc agggcaaatg taaagacggc ctcggggaat acacctgcac ctgtttagaa    240ggattcgaag gcaaaaactg tgaattattc acacggaagc tctgcagcct ggacaacggg    300gactgtgacc agttctgcca cgaggaacag aactctgtgg tgtgctcctg cgcccgcggg    360tacaccctgg ctgacaacgg caaggcctgc attcccacag ggccctaccc ctgtgggaaa    420cagaccctgg aacgcaggaa gaggaggaag aggatcgtgg gaggccagga atgcaaggac    480ggggagtgtc cctggcaggc cctgctcatc aatgaggaaa acgagggttt ctgtggtgga    540accattctga gcgagttcta catcctaacg gcagcccact gtctctacca agccaagaga    600ttcaaggtga gggtagggga ccggaacacg gagcaggagg agggcggtga ggcggtgcac    660gaggtggagg tggtcatcaa gcacaaccgg ttcacaaagg agacctatga cttcgacatc    720gccgtgctcc ggctcaagac ccccatcacc ttccgcatga acgtggcgcc tgcctgcctc    780cccgagcgtg actgggccga gtccacgctg atgacgcaga agacggggat tgtgagcggc    840ttcgggcgca cccacgagaa gggccggcag tccaccaggc tcaagatgct ggaggtgccc    900tacgtggacc gcaacagctg caagctgtcc agcagcttca tcatcaccca gaacatgttc    960tgtgccggct acgacaccaa gcaggaggat gcctgccagg gggacgcagg gggcccgcac   1020gtcacccgct tcaaggacac ctacttcgtg acaggcatcg tcagctgggg agagggctgt   1080gcccgtaagg ggaagtacgg gatctacacc aaggtcaccg ccttcctcaa gtggatcgac   1140aggtccatga aaaccagggg cttgcccaag gccaagagcc atgccccgga ggtcataacg   1200tcctctccat taaagtga                                                 1218</s400><s200><s210>17</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 17Arg Lys Arg Arg Lys Arg1               5</s400><s200><s210>18</s210><s211>7303</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polynucleotide</s223></s220></s200><s400> 18tctagacaca gtactcggcc acaccatggg gcgcccactg cacctcgtcc tgctcagtgc     60ctccctggct ggcctcctgc tgctcgggga aagtctgttc atccgcaggg agcaggccaa    120caacatcctg gcgagggtca cgagggccaa ttcctttctt ttctggaata aatacaaaga    180tggcgaccag tgtgagacca gtccttgcca gaaccagggc aaatgtaaag acggcctcgg    240ggaatacacc tgcacctgtt tagaaggatt cgaaggcaaa aactgtgaat tattcacacg    300gaagctctgc agcctggaca acggggactg tgaccagttc tgccacgagg aacagaactc    360tgtggtgtgc tcctgcgccc gcgggtacac cctggctgac aacggcaagg cctgcattcc    420cacagggccc tacccctgtg ggaaacagac cctggaacgc aggaagagga ggaagaggat    480cgtgggaggc caggaatgca aggacgggga gtgtccctgg caggccctgc tcatcaatga    540ggaaaacgag ggtttctgtg gtggaaccat tctgagcgag ttctacatcc taacggcagc    600ccactgtctc taccaagcca agagattcaa ggtgagggta ggggaccgga acacggagca    660ggaggagggc ggtgaggcgg tgcacgaggt ggaggtggtc atcaagcaca accggttcac    720aaaggagacc tatgacttcg acatcgccgt gctccggctc aagaccccca tcaccttccg    780catgaacgtg gcgcctgcct gcctccccga gcgtgactgg gccgagtcca cgctgatgac    840gcagaagacg gggattgtga gcggcttcgg gcgcacccac gagaagggcc ggcagtccac    900caggctcaag atgctggagg tgccctacgt ggaccgcaac agctgcaagc tgtccagcag    960cttcatcatc acccagaaca tgttctgtgc cggctacgac accaagcagg aggatgcctg   1020ccagggggac gcagggggcc cgcacgtcac ccgcttcaag gacacctact tcgtgacagg   1080catcgtcagc tggggagagg gctgtgcccg taaggggaag tacgggatct acaccaaggt   1140caccgccttc ctcaagtgga tcgacaggtc catgaaaacc aggggcttgc ccaaggccaa   1200gagccatgcc ccggaggtca taacgtcctc tccattaaag tgagatccca ctcggatccc   1260tattctatag tgtcacctaa atgctagagc tcgctgatca gcctcgactg tgccttctag   1320ttgccagcca tctgttgttt gcccctcccc cgtgccttcc ttgaccctgg aaggtgccac   1380tcccactgtc ctttcctaat aaaatgagga aattgcatcg cattgtctga gtaggtgtca   1440ttctattctg gggggtgggg tggggcagga cagcaagggg gaggattggg aagacaatag   1500caggcatgct ggggatgcgg tgggctctat ggcttctgag gcggaaagaa ccagctgggg   1560ctcgagcggc cgccccttct gaggcggaaa gaaccagctg tggaatgtgt gtcagttagg   1620gtgtggaaag tccccaggct ccccagcagg cagaagtatg caaagcatgc atctcaatta   1680gtcagcaacc aggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat   1740gcatctcaat tagtcagcaa ccatagtccc gcccctaact ccgcccatcc cgcccctaac   1800tccgcccagt tccgcccatt ctccgcccca tggctgacta atttttttta tttatgcaga   1860ggccgaggcc gcctcggcct ctgagctatt ccagaagtag tgaggaggct tttttggagg   1920cctaggcttt tgcaaaaaag ctagcttccc gctgccatca tggttcgacc attgaactgc   1980atcgtcgccg tgtcccaaaa tatggggatt ggcaagaacg gagacctacc ctggcctccg   2040ctcaggaacg agttcaagta cttccaaaga atgaccacaa cctcttcagt ggaaggtaaa   2100cagaatctgg tgattatggg taggaaaacc tggttctcca ttcctgagaa gaatcgacct   2160ttaaaggaca gaattaatat agttctcagt agagaactca aagaaccacc acgaggagct   2220cattttcttg ccaaaagttt ggatgatgcc ttaagactta ttgaacaacc ggaattggca   2280agtaaagtag acatggtttg gatagtcgga ggcagttctg tttaccagga agccatgaat   2340caaccaggcc accttagact ctttgtgaca aggatcatgc aggaatttga aagtgacacg   2400tttttcccag aaattgattt ggggaaatat aaacttctcc cagaataccc aggcgtcctc   2460tctgaggtcc aggaggaaaa aggcatcaag tataagtttg aagtctacga gaagaaagac   2520taacaggaag atgctttcaa gttctctgct cccctcctaa agctatgcat ttttataaga   2580ccatgggact tttgctggct ttagatcccg cggagatcca gacatgataa gatacattga   2640tgagtttgga caaaccacaa ctagaatgca gtgaaaaaaa tgctttattt gtgaaatttg   2700tgatgctatt gctttatttg taaccattat aagctgcaat aaacaagtta acaacaacaa   2760ttgcattcat tttatgtttc aggttcaggg ggaggtgtgg gaggtttttt aaagcaagta   2820aaacctctac aaatgtggta tggctgatta tgagctccag cttttgttcc ctttagtgag   2880ggttaattgc gcgcttggcg taatcatggt catagctgtt tcctgtgtga aattgttatc   2940cgctcacaat tccacacaac atacgagccg gaagcataaa gtgtaaagcc tggggtgcct   3000aatgagtgag ctaactcaca ttaattgcgt tgcgctcact gcccgctttc cagtcgggaa   3060acctgtcgtg ccagctgcat taatgaatcg gccaacgcgc ggggagaggc ggtttgcgta   3120ttgggcgctc ttccgcttcc tcgctcactg actcgctgcg ctcggtcgtt cggctgcggc   3180gagcggtatc agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg   3240caggaaagaa catgtgagca aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt   3300tgctggcgtt tttccatagg ctccgccccc ctgacgagca tcacaaaaat cgacgctcaa   3360gtcagaggtg gcgaaacccg acaggactat aaagatacca ggcgtttccc cctggaagct   3420ccctcgtgcg ctctcctgtt ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc   3480cttcgggaag cgtggcgctt tctcatagct cacgctgtag gtatctcagt tcggtgtagg   3540tcgttcgctc caagctgggc tgtgtgcacg aaccccccgt tcagcccgac cgctgcgcct   3600tatccggtaa ctatcgtctt gagtccaacc cggtaagaca cgacttatcg ccactggcag   3660cagccactgg taacaggatt agcagagcga ggtatgtagg cggtgctaca gagttcttga   3720agtggtggcc taactacggc tacactagaa ggacagtatt tggtatctgc gctctgctga   3780agccagttac cttcggaaaa agagttggta gctcttgatc cggcaaacaa accaccgctg   3840gtagcggtgg tttttttgtt tgcaagcagc agattacgcg cagaaaaaaa ggatctcaag   3900aagatccttt gatcttttct acggggtctg acgctcagtg gaacgaaaac tcacgttaag   3960ggattttggt catgagatta tcaaaaagga tcttcaccta gatcctttta aattaaaaat   4020gaagttttaa atcaatctaa agtatatatg agtaaacttg gtctgacagt taccaatgct   4080taatcagtga ggcacctatc tcagcgatct gtctatttcg ttcatccata gttgcctgac   4140tccccgtcgt gtagataact acgatacggg agggcttacc atctggcccc agtgctgcaa   4200tgataccgcg agacccacgc tcaccggctc cagatttatc agcaataaac cagccagccg   4260gaagggccga gcgcagaagt ggtcctgcaa ctttatccgc ctccatccag tctattaatt   4320gttgccggga agctagagta agtagttcgc cagttaatag tttgcgcaac gttgttgcca   4380ttgctacagg catcgtggtg tcacgctcgt cgtttggtat ggcttcattc agctccggtt   4440cccaacgatc aaggcgagtt acatgatccc ccatgttgtg caaaaaagcg gttagctcct   4500tcggtcctcc gatcgttgtc agaagtaagt tggccgcagt gttatcactc atggttatgg   4560cagcactgca taattctctt actgtcatgc catccgtaag atgcttttct gtgactggtg   4620agtactcaac caagtcattc tgagaatagt gtatgcggcg accgagttgc tcttgcccgg   4680cgtcaatacg ggataatacc gcgccacata gcagaacttt aaaagtgctc atcattggaa   4740aacgttcttc ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc agttcgatgt   4800aacccactcg tgcacccaac tgatcttcag catcttttac tttcaccagc gtttctgggt   4860gagcaaaaac aggaaggcaa aatgccgcaa aaaagggaat aagggcgaca cggaaatgtt   4920gaatactcat actcttcctt tttcaatatt attgaagcat ttatcagggt tattgtctca   4980tgagcggata catatttgaa tgtatttaga aaaataaaca aataggggtt ccgcgcacat   5040ttccccgaaa agtgccacct gggaaattgt aaacgttaat attttgttaa aattcgcgtt   5100aaatttttgt taaatcagct cattttttaa ccaataggcc gaaatcggca aaatccctta   5160taaatcaaaa gaatagaccg agatagggtt gagtgttgtt ccagtttgga acaagagtcc   5220actattaaag aacgtggact ccaacgtcaa agggcgaaaa accgtctatc agggcgatgg   5280cccactacgt gaaccatcac cctaatcaag ttttttgggg tcgaggtgcc gtaaagcact   5340aaatcggaac cctaaaggga gcccccgatt tagagcttga cggggaaagc cggcgaacgt   5400ggcgagaaag gaagggaaga aagcgaaagg agcgggcgct agggcgctgg caagtgtagc   5460ggtcacgctg cgcgtaacca ccacacccgc cgcgcttaat gcgccgctac agggcgcgtc   5520gcgccattcg ccattcaggc tgcgcaactg ttgggaaggg cgatcggtgc gggcctcttc   5580gctattacgc cagctggcga aagggggatg tgctgcaagg cgattaagtt gggtaacgcc   5640agggttttcc cagtcacgac gttgtaaaac gacggccagt gagcgcgcgt aatacgactc   5700actatagggc gaattggaat taattcgctg ggctgagacc cgcagaggaa gacgctctag   5760ggatttgtcc cggactagcg agatggcaag gctgaggacg ggaggctgat tgagaggcga   5820aggtacaccc taatctcaat acaacccttg gagctaagcc agcaatggta gagggaagat   5880tctgcacgtc ccttccaggc ggcctccccg tcaccaccca ccccaacccg ccccgaccgg   5940agctgagagt aattcataca aaaggactcg cccctgcctt ggggaatccc agggaccgtc   6000gttaaactcc cactaacgta gaacccagag atcgctgcgt tcccgccccc tcacccgccc   6060gctctcgtca tcactgaggt ggagaagagc atgcgtgagg ctccggtgcc cgtcagtggg   6120cagagcgcac atcgcccaca gtccccgaga agttgggggg aggggtcggc aattgaaccg   6180gtgcctagag aaggtggcgc ggggtaaact gggaaagtga tgtcgtgtac tggctccgcc   6240tttttcccga gggtggggga gaaccgtata taagtgcagt agtcgccgtg aacgttcttt   6300ttcgcaacgg gtttgccgcc agaacacagg taagtgccgt gtgtggttcc cgcgggcctg   6360gcctctttac gggttatggc ccttgcgtgc cttgaattac ttccacgccc ctggctgcag   6420tacgtgattc ttgatcccga gcttcgggtt gaaagtgggt gggagagttc gaggccttgc   6480gcttaaggag ccccttcgcc tcgtgcttga gttgaggcct ggcttgggcg ctggggccgc   6540cgcgtgcgaa tctggtggca ccttcgcgcc tatctcgctg ctttcgataa gtctctagcc   6600atttaaaatt tttgatgacc tgctgcgacg ctttttttct ggcaagatag tcttgtaaat   6660gcgggccaag atctgcacac tggtatttcg gtttttgggg ccgcgggcgg cgacggggcc   6720cgtgcgtccc agcgcacatg ttcggcgagg cggggcctgc gagcgcggcc accgagaatc   6780ggacgggggt agtctcaagc tggccggcct gctctggtgc ctggcctcgc gccgccgtgt   6840atcgccccgc cctgggcggc aaggctggcc cggtcggcac cagttgcgtg agcggaaaga   6900tggccgcttc ccggccctgc tgcagggagc tcaaaatgga ggacgcggcg ctcgggagag   6960cgggcgggtg agtcacccac acaaaggaaa agggcctttc cgtcctcagc cgtcgcttca   7020tgtgactcca cggagtaccg ggcgccgtcc aggcacctcg attagttctc gagcttttgg   7080agtacgtcgt ctttaggttg gggggagggg ttttatgcga tggagtttcc ccacactgag   7140tgggtggaga ctgaagttag gccagcttgg cacttgatgt aattctcctt ggaatttgcc   7200ctttttgagt ttggatcttg gttcattctc aagcctcaga cagtggttca aagttttttt   7260cttccatttc aggtgtcgtg aaaactaccc ctaaaagcca aat                     7303</s400><s200><s210>19</s210><s211>405</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 19Met Gly Arg Pro Leu His Leu Val Leu Leu Ser Ala Ser Leu Ala Gly1               5                   10                  15Leu Leu Leu Leu Gly Glu Ser Leu Phe Ile Arg Arg Glu Gln Ala Asn            20                  25                  30Asn Ile Leu Ala Arg Val Thr Arg Ala Asn Ser Phe Leu Phe Trp Asn        35                  40                  45Lys Tyr Lys Asp Gly Asp Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln    50                  55                  60Gly Lys Cys Lys Asp Gly Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu65                  70                  75                  80Gly Phe Glu Gly Lys Asn Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser                85                  90                  95Leu Asp Asn Gly Asp Cys Asp Gln Phe Cys His Glu Glu Gln Asn Ser            100                 105                 110Val Val Cys Ser Cys Ala Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys        115                 120                 125Ala Cys Ile Pro Thr Gly Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu    130                 135                 140Arg Arg Lys Arg Arg Lys Arg Ile Val Gly Gly Gln Glu Cys Lys Asp145                 150                 155                 160Gly Glu Cys Pro Trp Gln Ala Leu Leu Ile Asn Glu Glu Asn Glu Gly                165                 170                 175Phe Cys Gly Gly Thr Ile Leu Ser Glu Phe Tyr Ile Leu Thr Ala Ala            180                 185                 190His Cys Leu Tyr Gln Ala Lys Arg Phe Lys Val Arg Val Gly Asp Arg        195                 200                 205Asn Thr Glu Gln Glu Glu Gly Gly Glu Ala Val His Glu Val Glu Val    210                 215                 220Val Ile Lys His Asn Arg Phe Thr Lys Glu Thr Tyr Asp Phe Asp Ile225                 230                 235                 240Ala Val Leu Arg Leu Lys Thr Pro Ile Thr Phe Arg Met Asn Val Ala                245                 250                 255Pro Ala Cys Leu Pro Glu Arg Asp Trp Ala Glu Ser Thr Leu Met Thr            260                 265                 270Gln Lys Thr Gly Ile Val Ser Gly Phe Gly Arg Thr His Glu Lys Gly        275                 280                 285Arg Gln Ser Thr Arg Leu Lys Met Leu Glu Val Pro Tyr Val Asp Arg    290                 295                 300Asn Ser Cys Lys Leu Ser Ser Ser Phe Ile Ile Thr Gln Asn Met Phe305                 310                 315                 320Cys Ala Gly Tyr Asp Thr Lys Gln Glu Asp Ala Cys Gln Gly Asp Ala                325                 330                 335Gly Gly Pro His Val Thr Arg Phe Lys Asp Thr Tyr Phe Val Thr Gly            340                 345                 350Ile Val Ser Trp Gly Glu Gly Cys Ala Arg Lys Gly Lys Tyr Gly Ile        355                 360                 365Tyr Thr Lys Val Thr Ala Phe Leu Lys Trp Ile Asp Arg Ser Met Lys    370                 375                 380Thr Arg Gly Leu Pro Lys Ala Lys Ser His Ala Pro Glu Val Ile Thr385                 390                 395                 400Ser Ser Pro Leu Lys                405</s400><s200><s210>20</s210><s211>393</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MOD_RES</s221><s222>(324)..(324)</s222><s223>Dehydroalanine</s223></s220></s200><s400> 20Ala Asn Ser Phe Leu Glu Glu Met Lys Lys Gly His Leu Glu Arg Glu1               5                   10                  15Cys Met Glu Glu Thr Cys Ser Tyr Glu Glu Ala Arg Glu Val Phe Glu            20                  25                  30Asp Ser Asp Lys Thr Asn Glu Phe Trp Asn Lys Tyr Lys Asp Gly Asp        35                  40                  45Gln Cys Glu Thr Ser Pro Cys Gln Asn Gln Gly Lys Cys Lys Asp Gly    50                  55                  60Leu Gly Glu Tyr Thr Cys Thr Cys Leu Glu Gly Phe Glu Gly Lys Asn65                  70                  75                  80Cys Glu Leu Phe Thr Arg Lys Leu Cys Ser Leu Asp Asn Gly Asp Cys                85                  90                  95Asp Gln Phe Cys His Glu Glu Gln Asn Ser Val Val Cys Ser Cys Ala            100                 105                 110Arg Gly Tyr Thr Leu Ala Asp Asn Gly Lys Ala Cys Ile Pro Thr Gly        115                 120                 125Pro Tyr Pro Cys Gly Lys Gln Thr Leu Glu Arg Ile Val Gly Gly Gln    130                 135                 140Glu Cys Lys Asp Gly Glu Cys Pro Trp Gln Ala Leu Leu Ile Asn Glu145                 150                 155                 160Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Ser Glu Phe Tyr Ile                165                 170                 175Leu Thr Ala Ala His Cys Leu Tyr Gln Ala Lys Arg Phe Lys Val Arg            180                 185                 190Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Gly Glu Ala Val His        195                 200                 205Glu Val Glu Val Val Ile Lys His Asn Arg Phe Thr Lys Glu Thr Tyr    210                 215                 220Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile Thr Phe Arg225                 230                 235                 240Met Asn Val Ala Pro Ala Cys Leu Pro Glu Arg Asp Trp Ala Glu Ser                245                 250                 255Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe Gly Arg Thr            260                 265                 270His Glu Lys Gly Arg Gln Ser Thr Arg Leu Lys Met Leu Glu Val Pro        275                 280                 285Tyr Val Asp Arg Asn Ser Cys Lys Leu Ser Ser Ser Phe Ile Ile Thr    290                 295                 300Gln Asn Met Phe Cys Ala Gly Tyr Asp Thr Lys Gln Glu Asp Ala Cys305                 310                 315                 320Gln Gly Asp Ala Gly Gly Pro His Val Thr Arg Phe Lys Asp Thr Tyr                325                 330                 335Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala Arg Lys Gly            340                 345                 350Lys Tyr Gly Ile Tyr Thr Lys Val Thr Ala Phe Leu Lys Trp Ile Asp        355                 360                 365Arg Ser Met Lys Thr Arg Gly Leu Pro Lys Ala Lys Ser His Ala Pro    370                 375                 380Glu Val Ile Thr Ser Ser Pro Leu Lys385                 390</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000958A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000958</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17305074</doc-number><date>20210630</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>48</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>375</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>593</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>33</main-group><subgroup>30</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>33</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>46</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>115</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>21</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>17</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>105</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>16</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>155</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>23</class><subclass>L</subclass><main-group>29</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>4873</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>375</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>593</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>33</main-group><subgroup>30</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>33</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>46</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>0056</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20160801</date></cpc-version-indicator><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>115</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20160801</date></cpc-version-indicator><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>21</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20160801</date></cpc-version-indicator><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>17</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20160801</date></cpc-version-indicator><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>105</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20160801</date></cpc-version-indicator><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>16</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20160801</date></cpc-version-indicator><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>155</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20160801</date></cpc-version-indicator><section>A</section><class>23</class><subclass>L</subclass><main-group>29</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20160801</date></cpc-version-indicator><section>A</section><class>23</class><subclass>L</subclass><main-group>33</main-group><subgroup>40</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>23</class><subclass>V</subclass><main-group>2002</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">Immune Booster Food Supplement</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Karnwie-Tuah</last-name><first-name>Daaniel</first-name><address><city>Santa Clarita</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Karnwie-Tuah</last-name><first-name>Daaniel</first-name><address><city>Santa Clarita</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention discloses a capsule supplement that can boost the immune system and offer advanced protection. The food supplement is a food composition for oral administration as an anti-inflammatory and immune booster. The invention achieves the results by using its anti-inflammatory properties, fats, carbohydrates, protein, fruits, minerals and vitamins, antioxidant and is fortified with: vitamin C, vitamin D, zinc, and bromelain. It improves overall health and wellness. The said supplement increases the body defenses against viruses and other illnesses. Unlike therapeutic interventions, this supplement composes of ingredients that are in the food category, which is the primary source of nutrients for the human body. It helps the body maintains its healthy normal functions by using its natural source of sustenance.</p></abstract><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">TECHNICAL FIELD</heading><p id="p-0002" num="0001">The present invention relates to food supplements, and particularly to an immune booster food supplement formulated to improve immune system and offer advanced protection as well as improving the overall human health.</p><heading id="h-0002" level="1">BACKGROUND ART</heading><p id="p-0003" num="0002">The supplements currently available are used in combinations to achieve similar results. For example, multivitamin, and many other individual extracts are used combinations because no single one is effective enough to provide the improvement needed to achieve the results. The currently available supplements that support the immune function rely on heavily on the combination of regular vitamins in addition to few fruits or vegetables that have little to do with the immune system.</p><p id="p-0004" num="0003">A study carried by NIH researchers reveals that &#x201c;Vitamin C in humans must be ingested for survival. Vitamin C is an electron donor, and this property accounts for all its known functions. As an electron donor, vitamin C is a potent water-soluble antioxidant in humans. Antioxidant effects of vitamin C have been demonstrated in many experiments in vitro. Human diseases such as atherosclerosis and cancer might occur in part from oxidant damage to tissues.&#x201d; Padayatty S J, et al., &#x201c;Vitamin C as an antioxidant: evaluation of its role in disease prevention,&#x201d; J Am Coll Nutr. February 2003; 22(1):18-35.</p><p id="p-0005" num="0004">The immune system's role is to defend the body against external and internal aggression. These attacks penetrate at the level of trade surfaces or lesions in the natural barriers of protection. The biological attacks are caused by foreign organisms, pathogenic or not, such as microorganisms (bacteria, fungi), viruses or parasites (protozoa, helminths). The internal aggressions are the fact of cells become tumorous or whose function puts directly or indirectly the normal components of the organism (the self) in danger. The aging of the immune system is characterized by thymic involution, which begins at puberty and is almost complete at middle age. This involution results in a reduction of the size of the thymus and a progressive replacement of the lymphocyte and vascular space by adipose tissue.</p><p id="p-0006" num="0005">Further, the pandemic has been accelerating demand for immunity boosting products and ingredients. Functional ingredients suppliers have revealed that the coronavirus has caused 75 percent of consumers to seek out healthier foods and beverages, and according to Google Trends data, searches for the combined terms, &#x2018;food&#x2019; and &#x2018;immune system&#x2019; skyrocketed by 670 percent between February and March, 2021. But, while COVID-19 is piquing consumer interest in a variety of trendy products, not all are worth the hype. The following are the most popular trends in the immunity-boosting market with the scientific evidence, or lack thereof, to support their claims. Wellness shots are small servings of concentrated juices consisting of ingredients that are considered to have beneficial properties. Immune boosting wellness shots typically have one or more of a number of ingredients such as ginger, turmeric, wheatgrass, citrus, echinacea, cayenne pepper or apple cider vinegar. Global consumer surveys conducted by InsightsNow, Inc. before and during the pandemic reveal that COVID-19 has affected consumer perceptions of health and wellness, creating a renewed interest in functional foods or foods that are fortified, enriched or enhanced, providing health benefits beyond the provision of basic nutrients.</p><p id="p-0007" num="0006">A few prior art exists in this field of technology.</p><p id="p-0008" num="0007">A French patent number FR2882896A1 filed in 2005 by LARENA S A discloses a supplementary food composition, useful e.g. to treat and/or prevent sarcopenia, comprises proteins rich in branched amino acids, ginsenosides, zinc, selenium, vitamins (B complex, D, C and E), algal extract, polyphenols and carotenoids. It claims 1. Substitute food composition comprising at least natural proteins rich in branched-chain amino acids, amino acids such as arginine and glutamine, ginsenosides, zinc, selenium, vitamins B1, B2, B3, B5, B6, B8, B9 and B12, vitamin D, vitamin C, vitamin E, seaweed extract, polyphenols and carotenoids. However, although, it claims the use of Vitamin C, Vitamin D, Zinc and an antioxidant, it does not claim the use of bromelain.</p><p id="p-0009" num="0008">U.S. patent number US20080095757A1 filed in 2007 by FRUITFUL YIELD Inc discloses use of Vitamin C in a composition. It claims, 1. A composition comprising ascorbate and at least one ascorbate-glucose transport enhancer. 2. The composition of claim <b>1</b>, wherein the ascorbate is in the form of vitamin C, ascorbic acid, L-ascorbic acid, L-xylo-ascorbic acid, L-threo-hex-2-enoic acid &#x3b3;-lactone, an ascorbyl ester, ascorbyl palmitate, an ascorbyl phosphate ester, a reacted or blended mineral ascorbate, dehydroascorbate, or a vitamin C metabolite, and 3. The composition of claim <b>2</b>, wherein the mineral ascorbate is calcium ascorbate, magnesium ascorbate, zinc ascorbate, sodium ascorbate, or potassium ascorbate. Even if it discloses and claims the use of Vitamin C, Zinc, Bromelain and an antioxidant, it fails to teach about the use of Vitamin D.</p><p id="p-0010" num="0009">It is now clear that the above supplements currently available are used in combinations to achieve similar results. For example, multivitamin, and many other individual extracts are used combinations because no single one is effective enough to provide the improvement needed to achieve the results. Therefore, there is need to develop a more effective food supplement that can boost human immunity against many diseases including COVID-19.</p><heading id="h-0003" level="1">OBJECTIVES OF THE INVENTION</heading><p id="p-0011" num="0010">It is an object of the present invention to provide a supplement that can protect body by its ability to fight harmful bacteria and viruses, protect cells from the damage and improve healing. A single capsule performs many functions that are usually associated with several different supplements or medications.</p><p id="p-0012" num="0011">The other object of the present invention is to avail a supplement that increases the body defenses against viruses and other illnesses.</p><heading id="h-0004" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0013" num="0012">The following summary is an explanation of some of the general inventive steps for the materials, method, and apparatus in the description. This summary is not an extensive overview of the invention and does not intend to limit the scope beyond what is described and claimed as a summary.</p><p id="p-0014" num="0013">In the first aspect, the present invention discloses an immune booster food supplement, comprising fats, carbohydrates, protein, fruits, minerals and vitamins, antioxidant and fortified with: vitamin C, vitamin D, sodium, zinc, and bromelain. The said capsule supplement can boost the immune system and offer advanced protection.</p><p id="p-0015" num="0014">In another aspect, the present invention discloses a food supplement in form of a composition for oral administration as an anti-inflammatory and immune booster by using anti-inflammatory properties of fats, carbohydrates, protein, fruits, minerals and vitamins, antioxidant and is fortified with: vitamin C, vitamin D, zinc, and bromelain.</p><p id="p-0016" num="0015">In a third aspect of the present invention is to improve overall health and wellness by providing a supplement that composes of ingredients that are in the food category, which is the primary source of nutrients for the human body, unlike therapeutic interventions. Unlike therapeutic interventions, this supplement composes of ingredients that are in the food category, which is the primary source of nutrients for the human body. It helps the body maintains its healthy normal functions by using its natural source of sustenance.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0005" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p-0017" num="0016">Studies have shown that a significant number of Americans do not consume sufficient amounts of Vitamins C and D. Most of their daily diet lack Zinc. They rarely consume adequate servings of fruits and vegetables including pineapple, ginger, lemon, lime and bromelain. Increasing the amount of these components consumed in a standard daily diet is one way to rectify this deficiency. Dietary supplements are another option, and there are a number of commercially available vitamin C and vitamin D supplements in the market. The effectiveness of such supplements is limited, however, by the absorption rates and transport efficiencies of the body.</p><p id="p-0018" num="0017">In one embodiment, the present invention describes an immune booster food supplement, comprising fats, carbohydrates, protein, fruits, minerals and vitamins, antioxidant and fortified with: vitamin C, vitamin D, sodium, zinc, and bromelain. The said supplement is as a capsule that boost the immune system and offer advanced protection. It achieves the results by using its anti-inflammatory properties, fats, carbohydrates, protein, fruits, minerals and vitamins, antioxidant and is fortified with: vitamin C, vitamin D, zinc, and bromelain which improves overall health and wellness.</p><p id="p-0019" num="0018">In another embodiment, the invention reveals a supplement that contains the blend of gluten free, allergen free, non-GMO, natural ingredients comprising their unique functions as follows:</p><p id="p-0020" num="0019">Vitamin C is an antioxidant. It protects your cells from the damage caused by free radicals, improves your the immune system, and supports your body's healing process.</p><p id="p-0021" num="0020">Vitamin D helps the immune system to fight off invading bacteria and viruses, contains the required nutrients for good health, helps your body to absorb calcium, a building blocks for strong bones, protects you from developing osteoporosis, helps your nerves to carry messages between your brain and your body, prevents heart disease and high blood pressure and prevents cancer, such as colon, prostate and breast cancers.</p><p id="p-0022" num="0021">Zinc helps the immune system fight off invading bacteria and viruses, helps your metabolism function, supports your sense of taste and smell and helps with wound healing.</p><p id="p-0023" num="0022">Pineapple is loaded with antioxidants and helps digestion, anti-Inflammatory and speeds recovery after surgery or exercise. It fortifies the immune body functions.</p><p id="p-0024" num="0023">Potassium is equally vital to the body functions.</p><p id="p-0025" num="0024">Ginger is used to fight harmful bacteria and viruses. It is an anti-inflammatory and antioxidant. It helps in weight management, reduces risk of heart disease and reduces LDL (bad) cholesterol</p><p id="p-0026" num="0025">Lemon has high Vitamin C content. It is also used in weight management and reduces the risk of heart diseases, Anaemia, Kidney stones, digestive issues, and cancer.</p><p id="p-0027" num="0026">Bromelain acts as an anti-inflammatory and improves your allergies, indigestion, supports your body healing process and promotes the overall health.</p><p id="p-0028" num="0027">Lime has high antioxidants. It improves your immune system, reduces your heart disease risk factors, prevents kidney stones, aids in iron absorption and promotes healthy skin.</p><p id="p-0029" num="0028">Compositions disclosed herein include compounds with anti-inflammatory properties, minerals and vitamins, antioxidant and is fortified with: vitamin C, vitamin D, zinc, and bromelain. The preferred amounts of are depicted in the table below showing Example 1:</p><heading id="h-0006" level="1">EXAMPLE 1: FOOD SUPPLEMENT COMPOSITION</heading><p id="p-0030" num="0029">60 Serving per Container: Serving size 1 Capsule</p><p id="p-0031" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="14pt" align="center"/><colspec colname="2" colwidth="98pt" align="left"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><thead><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Amount per Serving</entry><entry>% Daily</entry></row><row><entry>No</entry><entry/><entry>in Calories</entry><entry>Value Intake</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="14pt" align="char" char="."/><colspec colname="2" colwidth="98pt" align="left"/><colspec colname="3" colwidth="35pt" align="right"/><colspec colname="4" colwidth="28pt" align="left"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>1</entry><entry>Total Fat</entry><entry>&#x3c;1</entry><entry>g</entry><entry>&#x3c;1%</entry></row><row><entry/><entry>Saturated Fat</entry><entry>&#x3c;1</entry><entry>g</entry><entry>&#xb1;</entry></row><row><entry/><entry>Trans Fat</entry><entry>&#x3c;1</entry><entry>g</entry><entry>&#x3c;1%</entry></row><row><entry>2</entry><entry>Cholesterol</entry><entry>&#x3c;1</entry><entry>g</entry><entry>&#x3c;1%</entry></row><row><entry/><entry>Sodium</entry><entry>1.0</entry><entry>mg</entry><entry>&#x2002;0%</entry></row><row><entry>3</entry><entry>Total Carbohydrate</entry><entry>&#x3c;1</entry><entry>g</entry><entry>&#x3c;1%</entry></row><row><entry/><entry>Dietary Fiber</entry><entry>&#x3c;1</entry><entry>g</entry><entry>&#x3c;1%</entry></row><row><entry/><entry>Total Sugars</entry><entry>&#x3c;1</entry><entry>g</entry><entry>&#x3c;1%</entry></row><row><entry/><entry>Includes added Sugars</entry><entry>&#x3c;1</entry><entry>g</entry><entry>&#x2014;</entry></row><row><entry>4</entry><entry>Protein</entry><entry>&#x3c;1</entry><entry>g</entry><entry>&#x3c;1%</entry></row><row><entry>5</entry><entry>Vitamin C (as Ascorbic Acid)</entry><entry>40.0</entry><entry>mg</entry><entry>44%</entry></row><row><entry>6</entry><entry>Vitamin D3 (as Cholescalciferol)</entry><entry>12.5</entry><entry>mcg</entry><entry>63%</entry></row><row><entry>7</entry><entry>Zinc (as Zinc Oxide)</entry><entry>25</entry><entry>mg</entry><entry>227%&#x2002;</entry></row><row><entry>8</entry><entry>Bromelain 600 GDU</entry><entry>100.0</entry><entry>mg</entry><entry>&#x2014;</entry></row><row><entry>9</entry><entry>Pineapple 200 Sieve</entry><entry>100.0</entry><entry>mg</entry><entry>&#xb1;</entry></row><row><entry>10</entry><entry>Ginger Powder</entry><entry>100.0</entry><entry>mg</entry><entry>&#xb1;</entry></row><row><entry>11</entry><entry>Lime Powder</entry><entry>100.0</entry><entry>mg</entry><entry>&#xb1;</entry></row><row><entry>12</entry><entry>Lemon Powder</entry><entry>120.0</entry><entry>mg</entry><entry>&#xb1;</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry namest="1" nameend="5" align="left" id="FOO-00001">NB: The % Daily Value (DV) are based on a 2,000 Calorie Diet.</entry></row><row><entry namest="1" nameend="5" align="left" id="FOO-00002">&#xb1; Daily Value not established</entry></row></tbody></tgroup></table></tables></p><p id="p-0032" num="0030">In at least one particularly preferred embodiment, a composition includes Vitamin C in an amount from about 34% of daily intake by weight of actives to about 54% of daily intake by weight of actives and at least Vitamin D3 in an amount from about 53% of daily intake of by weight of actives to about 73% of daily intake by weight of actives. Zinc in an amount from about 217% of daily intake by weight of actives to about 137% of daily intake by weight of actives. Pineapple in an amount from about 90 mg by weight of actives to about 110 mg by weight of actives. Ginger powder in an amount from about 90 mg by weight of actives to about 110 mg by weight of actives. Lime powder in an amount from about 90 mg by weight of actives to about 110 mg by weight of actives. Lemon powder in an amount from about 100 mg by weight of actives to about 120 mg by weight of actives.</p><p id="p-0033" num="0031">Dietary fibres in an amount below &#x3c;1 g or daily intake of &#x3c;1% by weight of actives. Saturated fats in an amount below &#x3c;1 g or daily intake of &#x3c;1% by weight of actives. Proteins in an amount below &#x3c;1 g or daily intake of &#x3c;1% by weight of actives. Saturated fats in an amount below &#x3c;1 g or daily intake of &#x3c;1% or daily intake of &#x3c;1% by weight of actives. The total weight of actives is determined by the total weight of all compositional components providing Vitamin C and D and all compositional components. The total weight percentages of all components providing nutrients and other components of a composition should thus equal 100%. Compositions disclosed herein can be provided in any suitable dosage form. Preferably compositions are provided in an oral dosage form or a topical dosage form. For example, compositions can be in a dosage form that is a powder, a microencapsulated powder, granules, a granulated powder, a capsule, a softgel capsule, a two-piece capsule, a pre-blended mixture of ingredients, or a blended mixture of ingredients in the capsule.</p><p id="p-0034" num="0032">In a final embodiment, the invention provides a use of the above immune booster food supplement composition for the preparation of a food composition, a food supplement, or a dietary product for the prevention and/or treating declining immune system in the elderly, sarcopenia, preventing the decline of the immune system, preventing immunoscenescence, preventing the decline of cellular immune responses, preventing and/or reducing the number of infectious episodes, to restore antioxidant status in the elderly.</p><heading id="h-0007" level="1">INDUSTRIAL APPLICATION</heading><p id="p-0035" num="0033">The present invention applies to food industry. The invention provides a supplement that has the ability to fight harmful bacteria and viruses. It has the capacity to protect cells from the damage and improve healing. A single capsule performs many functions that are usually associated with several different supplements or medications.</p><p id="p-0036" num="0034">The supplement increases the body defenses against viruses and other illnesses. Unlike therapeutic interventions, this supplement composes of ingredients that are in the food category, which is the primary source of nutrients for the human body. It helps the body maintains its healthy normal functions by using its natural source of sustenance.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An immune booster food supplement, comprising fats, carbohydrates, protein, fruits, minerals and vitamins, antioxidant and fortified with: vitamin C, vitamin D, sodium, zinc, and bromelain</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the vitamin C is in an amount from about 34% of daily intake by weight of actives to about 54% of daily intake by weight of actives.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the vitamin D3 is in an amount from about 53% of daily intake of by weight of actives to about 73% of daily intake by weight of actives.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the zinc is in an amount from about 217% of daily intake by weight of actives to about 137% of daily intake by weight of actives.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the pineapple in an amount from about 90 mg by weight of actives to about 110 mg by weight of actives.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the ginger powder is in an amount from about 90 mg by weight of actives to about 110 mg by weight of actives.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the lime powder is in an amount from about 90 mg by weight of actives to about 110 mg by weight of actives.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the lemon powder in an amount from about 100 mg by weight of actives to about 120 mg by weight of actives.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the carbohydrate is in the form of dietary fibres.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The immune booster food supplement according to <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the dietary fibres is in an amount below &#x3c;1 g or daily intake of &#x3c;1% by weight of actives.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the fat is in the form of saturated fats.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The immune booster food supplement according to <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein the saturated fats saturated fats is in an amount below &#x3c;1 g or daily intake of &#x3c;1% by weight of actives.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the protein is in an amount below &#x3c;1 g or daily intake of &#x3c;1% by weight of actives.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The immune booster food supplement according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the sodium is in an amount below &#x3c;1 g or daily intake of &#x3c;1% or daily intake of &#x3c;1% by weight of actives.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. An immune booster food supplement, wherein the total weight of actives is determined by the total weight of all compositional components fortified with Vitamins C and D and all compositional components further comprising at least fats, carbohydrates, protein, fruits, minerals and vitamins, antioxidant and, sodium, zinc, and bromelain.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The immune booster food supplement according to <claim-ref idref="CLM-00015">claim 15</claim-ref>, wherein the total weight percentages of all components providing nutrients and other components of a composition should thus equal 100%.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The immune booster food supplement according to <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the compositions is presented in any suitable dosage form.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The immune booster food supplement according to <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the compositions are preferably provided in an oral dosage form.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The immune booster food supplement according to <claim-ref idref="CLM-00018">claim 18</claim-ref>, wherein the oral dosage form is in form of a capsule.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The immune booster food supplement according to <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the capsule is in form is a powder, a microencapsulated powder, granules, a granulated powder, a soft gel capsule, a two-piece capsule, a pre-blended mixture of ingredients, or a blended mixture of ingredients in the capsule.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The use of an immune booster food supplement composition as described in any one of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00020">20</claim-ref>, for the preparation of a food composition, a food supplement, or a dietary product for the prevention and/or treating declining immune system in the elderly, sarcopenia, preventing the decline of the immune system, preventing immunoscenescence, preventing the decline of cellular immune responses, preventing and/or reducing the number of infectious episodes, to restore antioxidant status in the elderly.</claim-text></claim></claims></us-patent-application>